Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history.

Danaher Corporation’s (NYSE:DHR) second-quarter results, on the other hand, were marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digits adjusted EPS growth.

Both companies delivered encouraging quarterly results, but they are benefiting from very different growth drivers. Johnson & Johnson (NYSE:JNJ) is proving that it can successfully navigate patent-related headwinds through its newer medicines, while Danaher (NYSE:DHR) is betting on a recovery in life sciences and bioprocessing demand. The key question for investors is which growth story appears more durable heading into 2026.

Bull Case

Johnson & Johnson’s (NYSE:JNJ) pharmaceutical business was arguably the biggest contributor to its strong quarter, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding analysts’ estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, ​compared with $100.8 billion ⁠previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share.

The most encouraging sign for investors may be Johnson & Johnson’s (NYSE:JNJ) ability to absorb a significant patent-related decline in Stelara sales while still raising its full-year outlook. Revenue from Johnson & Johnson’s (NYSE:JNJ) Stelara, which treats psoriasis, Crohn’s disease, and ​other autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss. However, the company’s cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion. Strong performance from newer drugs such as Tremfya suggests the company’s pipeline is successfully offsetting losses from older products.

Unlike Johnson & Johnson’s (NYSE:JNJ) pharmaceutical-driven growth story, Danaher’s (NYSE:DHR) biggest positive came from its Life Sciences business, which delivered its strongest performance in several years. Danaher’s (NYSE:DHR) biggest positive was its Life Sciences business, which delivered its strongest performance in several years. Although bioprocessing revenue was affected by customer project timings, the underlying order trends remained strong, with bioprocessing orders growing mid-teens in the quarter. This shows that the underlying demand for bioprocessing remained strong, which includes consumables and equipment necessary to make biologic drugs.

Danaher Corporation (NYSE:DHR) stated that a little over $100 million of revenue has shifted into next year, primarily from the second and third quarters, suggesting that customer demand has been delayed rather than cancelled and could support future revenue growth. While the academic and government markets have largely stabilized, more supportive government policies would be essential to safely call it an inflection point.

Bear Case

Although both companies delivered solid quarterly results, their near-term risks differ meaningfully. Johnson & Johnson (NYSE:JNJ) is primarily dealing with product-specific and segment-level headwinds, whereas Danaher (NYSE:DHR) continues to face broader questions surrounding execution and the timing of a life sciences recovery.

Johnson & Johnson’s (NYSE:JNJ) MedTech segment was comparatively less impressive during the quarter, with sales slightly missing expectations. Management attributed some of the weakness to temporary headwinds, including inventory-related pressures in China that weighed on Electrophysiology sales and softer U.S. procedure trends affecting Abiomed. While Johnson & Johnson (NYSE:JNJ) expects these challenges to improve over time, investors may want to watch whether its MedTech business returns to its historical growth trajectory in the coming quarters. Sustained weakness in these businesses could make the company increasingly reliant on its pharmaceutical segment to drive growth.

In contrast, Danaher Corporation (NYSE:DHR) reported weaker-than-expected revenue in its biotechnology business and cut its full-year core revenue growth outlook. The company cut the upper end of its core revenue growth outlook range to 4% from 6% for the year, and maintained the lower end at 3%, primarily to take into account the effects of the weaker respiratory testing revenue. These headwinds partially overshadowed the company’s otherwise improving trends in the life sciences tools market at a time when pharmaceutical and biotech companies are increasing research and manufacturing spending following the post-pandemic slowdown.

Following the earnings, BofA told investors that while the overall total company numbers were “fine” and ahead of expectations, the result “was certainly messier than expected”, driven primarily by a miss in bioprocessing that caused the stock to tumble 11%. While the firm maintained a Buy rating on Danaher Corporation (NYSE:DHR), it cut the price target on the stock to $230 from $270, stating that the company now has to rebuild confidence in the execution and business. This holds especially true as “this is not the first setback/headwind to pop up in recent years” for the company.

What Does Hedge Fund Ownership Say?

Hedge fund positioning also reflects differing levels of institutional confidence in the two companies’ near-term outlooks. According to Insider Monkey data, Johnson & Johnson (NYSE:JNJ) seems to be growing in popularity among hedge funds, with its ownership going from 104 in fiscal Q4 2025 to 113 in fiscal Q1 2026. Some notable stakes for Johnson & Johnson (NYSE:JNJ) come from Fisher Asset Management, GQG Partners, and AQR Capital Management, with Balyasny Asset Management‘s position jumping by 1,411% to $146 million.

However, according to Insider Monkey’s extensive database tracking 1,022 hedge funds, Danaher Corporation’s (NYSE:DHR) hedge fund ownership dropped from 125 in fiscal Q4 2025 to 110 in fiscal Q1 2026. The total dollar value also dropped from $11.42 million to $10.11 million, suggesting that some institutional investors have become more cautious amid the company’s recent execution challenges.

The divergence in hedge fund sentiment mirrors the broader investment thesis for both stocks. Johnson & Johnson (NYSE:JNJ) appears to be benefiting from growing confidence in its pharmaceutical pipeline and raised guidance, while Danaher (NYSE:DHR) remains a longer-term recovery story that may require additional execution before institutional sentiment improves.

While we acknowledge the potential of JNJ to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than JNJ and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.